scFv-CH-CL-scFv

There are many potential uses for scFv-CH-CL-scFv in cancer immunotherapy, particularly in the synthesis of chimeric antigen receptors (CARs). A transmembrane structure, an endogenous signal transduction structure, and an exogenous antigen recognition structure (often a scFv or scFv-CH-CL-scFv) make up the artificially manufactured protein known as CAR. T cells can be transduced with CAR, which gives them the ability to identify and eliminate tumor cells that express particular antigens directly, bypassing the major histocompatibility complex (MHC). The US Food and Drug Administration (FDA) has currently licensed a number of CAR-T cell therapy products based on CD19-specific scFv or scFv-CH-CL-scFv for the treatment of recurrent or refractory B-cell malignancies. Furthermore, there are numerous CAR-T cell treatment products that are based on distinct scFv targets or scFv-CH-CL-scFv at various phases.